Isoprenoid biosynthesis is essential for Plasmodium falciparum (malaria) parasites and contains 19 multiple validated antimalarial drug targets, including a bifunctional farnesyl and geranylgeranyl 20 diphosphate synthase (FPPS/GGPPS). We identified MMV019313 as an inhibitor of 21 PfFPPS/GGPPS. Though PfFPPS/GGPPS is also inhibited by a class of bisphosphonate drugs, 22 MMV019313 has significant advantages for antimalarial drug development. MMV019313 has 23 superior physicochemical properties compared to charged bisphosphonates that have poor 24 bioavailability and strong bone affinity. We also show that it is highly selective for 25
Introduction 37
There is an urgent need for antimalarials with novel mechanisms-of-action to circumvent 38 resistance to frontline drugs. The biosynthesis of cellular isoprenoids is an essential process in 39
Plasmodium parasites that cause malaria. A number of antimalarial compounds target enzymes 40 PF3D7_0826400) catalyze the condensation of IPP and DMAPP into longer prenyl chains (Artz 48 et al., 2011; Jordão et al., 2013; Tonhosolo et al., 2005) . In particular, farnesyl pyrophosphate 49 synthase (FPPS) and geranylgeranyl pyrophosphate synthase (GGPPS) are key branch point 50 enzymes that synthesize C15 and C20 prenyl chains, respectively, for multiple downstream 51 enzymes. In Plasmodium parasites, these reactions are catalyzed by a single bifunctional 52 enzyme, the farnesyl/geranylgeranyl diphosphate synthase (Artz et al., 2011; Jordão et al., 2013) . Finally, prenyl chains are cyclized and/or conjugated to small molecule and protein 57 scaffolds by a variety of prenyltransferases to biosynthesize final isoprenoid products required 58 for parasite growth and replication. Tetrahydroquinolines (THQ) have been shown to potently 59 inhibit the Plasmodium protein farnesyltransferase (Eastman et al., 2005; Nallan et al., 60 2005) . Other inhibitors may interfere with isoprenoid biosynthesis indirectly by disrupting 61 transporters that supply starting substrates or export products or blocking pathways that provide 62 cofactors for isoprenoid biosynthetic enzymes. 63 Importantly fosmidomycin, bisphosphonates, and tetrahydroquinolines have all shown 64 efficacy in mouse models of malaria infection, validating the key importance of isoprenoid 65 biosynthesis as an antimalarial drug target (Jomaa et al., 1999; Nallan et al., 2005; No et al., 66 2012; Singh et al., 2010) . Fosmidomycin is currently being tested in human clinical trials, while 67 a THQ lead candidate was investigated in preclinical studies (Fernandes et al., 2015; Nallan et 68 al., 2005) . However, novel chemical scaffolds that disrupt isoprenoid biosynthetic pathways in 69
Plasmodium remain desirable to overcome unfavorable drug properties of these known 70 inhibitors. For example, bisphosphonates avidly bind bone mineral, and both fosmidomycin and 71
THQs have short half-lives in vivo (Sinigaglia et al., 2007; Tsuchiya et al., 1982; Van Voorhis et 72 al., 2007) . 73
In 2011 the Medicine for Malaria Venture (MMV) distributed the Open-Access Malaria 74
Box to accelerate antimalarial drug discovery (Spangenberg et al., 2013) . The Malaria Box 75 consists of 400 structurally diverse compounds, curated from >20,000 hits generated from large-76 scale screens, that inhibit the growth of blood-stage Plasmodium falciparum parasites (Gamo et 77 al., 2010; Guiguemde et al., 2010; Rottmann et al., 2010) . A major goal of sharing these 78 compounds was to facilitate elucidation of their antimalarial mechanism-of-action and open new 79 classes of validated chemical scaffolds and drug targets. Compounds that disrupt isoprenoid 80 metabolism can be detected by "rescue" of their growth inhibition upon supplementation of 81 isoprenoids in the growth media (Yeh and Derisi, 2011) . Previously, we and two other groups 82 screened the Malaria Box for compounds whose growth inhibition were rescued by addition of 83 IPP and identified MMV008138 (Bowman et al., 2014; Wu et al., 2015) . We and our 84 collaborators demonstrated that MMV008138 inhibits IspD, an enzyme in the MEP pathway that 85 produces IPP (Wu et al., 2015) . 86
Using a quantitative high-throughput screen (qHTS), we report a second compound in the 87 Malaria Box, MMV019313, that shows an IPP rescue phenotype but was not identified in 88 screens performed by other groups (Bowman et al., 2014 testing compounds at a single concentration is useful for identifying phenotypes that occur at a 101 threshold concentration (e.g. growth inhibition), growth rescue is expected to occur within a 102 specific range of concentrations. For example, doxycycline inhibits P. falciparum growth with an 103 EC 50 = 0.3 µM that increases to 3.2 µM upon addition of IPP (Yeh and Derisi, 2011) . At 104 concentrations <0.3 µM, doxycycline does not cause growth inhibition. However, at 105 concentrations >3.2 µM, it is no longer specific for its target and causes growth inhibition 106 through additional targets that cannot be IPP rescued. Therefore the concentration range in which 107 IPP rescue can be observed is greater than the EC 50 of the compound for its specific, IPP-108 rescuable target but less than that for any nonspecific targets. 109
To increase the sensitivity for detecting IPP chemical rescue, we screened the Malaria 110 Box for growth inhibition of blood-stage P. falciparum in the presence and absence of IPP over 111 8-12 drug concentrations from 0.01-27 µM (Table S1 ). Of 397 compounds tested (3 compounds  112 were not available), 383 showed growth inhibition at ≤27 µM. Initial hits showing IPP rescue of 113 growth inhibition at one or more drug concentrations were commercially sourced and retested. 114
Along with the previously reported compound, MMV008138, we confirmed a second compound 115 in the Malaria Box showing an IPP rescue phenotype, MMV019313 ( Figure 1A ). MMV019313 116 inhibited P. falciparum growth measured in a single replication cycle with EC 50 =268 nM (250-117 289 nM) in the absence of IPP; in the presence of IPP (200 µM), the EC 50 was over 13-fold more 118 at 3.6 µM (3.2-4.0 µM) ( Figure 1B) . Notably, at concentrations >3.6 µM, MMV019313 inhibits a 119 nonspecific target that can no longer be IPP rescued, which explains why it was not identified in 120 previous screens. 121
An unusual feature of blood-stage Plasmodium is that IPP can rescue complete loss of the 122 apicoplast, the plastid organelle which houses the MEP pathway, since production of IPP is the 123 only essential function of the apicoplast. Compounds like doxycycline that disrupt apicoplast 124 biogenesis cause growth inhibition rescued by IPP and result in parasites lacking an apicoplast 125 (Yeh and Derisi, 2011) . In contrast, inhibitors of isoprenoid biosynthesis, like fosmidomycin and 126 MMV008138, cause growth inhibition rescued by IPP with an intact apicoplast (Amberg-127 Johnson et al., 2017). We determined whether MMV019313 disrupted the biogenesis of the 128 apicoplast. Both the replication of the apicoplast genome and import of an apicoplast-targeted 129 GFP were intact in MMV019313-treated and IPP-rescued parasites ( Figure S1 ) (Yeh and Derisi, 130 2011) . Altogether MMV019313 causes growth inhibition rescued by IPP with no defect in 131
Though metabolomic profiling of MMV019313 has been performed, isoprenoid 137 intermediates were not examined so a specific disruption of these pathways could not be inferred 138 (Allman et al., 2016; Creek et al., 2016) . Instead to gain further insight into the mechanism-of-139 action of MMV019313, we identified mutations that confer resistance to MMV019313. Our 140 initial attempt to select drug-resistant parasites from a bulk culture of 10 10 parasites was not 141 successful, though this same protocol was effective in selecting drug resistance against 142 MMV008138 when performed in parallel (Wu et al., 2015) . Therefore, we turned to chemical 143 mutagenesis to increase the likelihood of selecting MMV019313-resistant parasites. Chemical 144 mutagenesis followed by whole genome sequencing to identify mutations has been successfully 145 employed to perform phenotypic screens in T. gondii but has not commonly been used in 146
Plasmodium parasites (Desai et al., 2005; Farrell et al., 2014; Inselburg, 1984; 1985) . We treated 147 10 8 P. falciparum W2 parasites with sub-lethal doses of ethyl methanesulfonate (EMS), an 148 alkylating agent. Because EMS is unstable, we tested a fresh batch of mutagen immediately prior 149 to treatment in a standard parasite growth inhibition assay to determine its EC 50 . We then 150 selected the EC 50 (2.025 mM) as the highest EMS concentration used and tested several lower 151 concentrations by serially diluting 3-fold. These relatively low concentrations were selected to 152 maximize the frequency of drug-resistant mutations while minimizing lethal mutations that 153 would result in a smaller pool of starting parasites or the presence of nonspecific passenger 154 mutations that would confound identification of causative mutations during whole genome 155 analysis. Following mutagenesis, parasites were continuously selected with a dose of 156 MMV019313 equal to its EC 75 in the presence of IPP for 32 days before removal of the drug. 157
This concentration was chosen to maximize selection pressure for developing resistance in the 158 IPP-rescuable target, while minimizing that for developing resistance in nonspecific targets. 159
Resistant parasites emerged in all mutagenized cultures one week after drug removal. In 160 these resistant populations, MMV019313 showed EC 50 values that ranged from 3-9-fold greater 161 than that observed in the initial susceptible population. Growth inhibition of two MMV019313-162 resistant populations which showed the highest levels of resistance at the lowest EMS 163 concentrations used (8.3 µM and 25 µM, designated 019313R1 and 019313R2 respectively) are 164 shown in Figure 2A . Significantly the EC 50 of MMV019313 in 019313R1 and 019313R2 was 165 similar to that observed in susceptible strains in the presence of IPP, and growth inhibition could 166 no longer be rescued by addition of IPP ( Figure S2 ). These results suggest that, as expected, 167 019313R1 and 019313R2 populations were completely resistant to inhibition of its specific IPP-168 rescuable target but had not developed resistance to inhibition of additional nonspecific targets. 169 This is the first example of using chemical mutagenesis to aid selection of drug-resistant 170 parasites in P. falciparum. 171 019313R1, 019313R2, and their respective mutagenized parent strains used to initiate 172 drug selection, WT1 and WT2, were subjected to whole-genome sequencing. Comparison of the 173 resistant and parent genome sequences identified a single nucleotide variant (SNV) common to 174 both resistance populations, which was present in 100% of reads in 019313R1 and 63% of reads 175 in 019313R2 but not present in either susceptible parent genomes (Table 1) . No other SNV were 176 detected at >40% prevalence in either resistant populations relative to the corresponding parent 177 populations (Table S2 ). The identified SNV was a T-to-A mutation in the gene PF3D7_1128400 178 characterized as a bifunctional FPPS/GGPPS and resulted in a Ser228-to-Thr change in the 179 protein ( Figure 2B ) (Artz et al., 2011; Jordão et al., 2013) . IPP is a known substrate of the 180 FPPS/GGPPS, and in the primary sequence Ser228 is adjacent to conserved KT residues and an 181
Asp-rich region required for catalysis in all homologous FPPS and GGPPS enzymes ( Figure 2C ). 182
PfFPPS/GGPPS was a strong candidate for further validation as the molecular target of 183
MMV019313. 184 185
Overexpression and an S228T variant of PfFPPS/GGPPS confers resistance to 186
MMV019313 187
We determined whether overexpression of wildtype PfFPPS/GGPPS was sufficient to 188 confer resistance to MMV019313. A transgene encoding FPPS/GGPPS-GFP under the control of 189 either the ribosomal L2 protein (RL2; PF3D7_1132700) or calmodulin (CaM; PF3D7_1434200) 190 promoter was integrated into an engineered attB locus in Dd2 attb parasites (Nkrumah et al., 191 2006 ). Expression of the CaM promoter is 10 to 50-fold greater across the life cycle than that of 192 the RL2 promoter based on RNA-seq data, resulting in appreciably greater FPPS/GGPPS-GFP 193 protein ( Figure S3A ) (Otto et al., 2010) . Therefore, we compared the effect of no, moderate 194 (RL2), and high (CaM) levels of FPPS/GGPPS-GFP overexpression on susceptibility to 195 MMV019313. As shown in Figure 3A and Table S3, indicating that complete resistance to inhibition of the specific IPP-rescuable target had been 201 achieved ( Figure S3B ). 202
We also determined whether the S228T variant of GGPPS confers MMV019313 203 resistance. Initially we attempted to introduce the S228T mutation into the fpps/ggpps gene in the 204 P. falciparum genome using CRISPR-Cas9 mutagenesis but were unable to recover mutant 205 parasites. As an alternative, we overexpressed the FPPS/GGPPS(S228T)-GFP variant using the 206 "moderate" RL2 promoter and compared its effect on MMV019313 susceptibility with that of 207 the wild-type RL2-FPPS/GGPPS-GFP. Overexpression of the FPPS/GGPPS(S228T)-GFP 208 variant, even at moderate levels, caused an 18-fold increase in the EC 50 which did not increase 209 further with IPP rescue, indicating that complete resistance to inhibition of the specific, IPP-210 rescuable target had been achieved ( Figure 3B and S3C; Table S3 ). Because moderate 211 overexpression of the S228T variant caused greater MMV019313 resistance than moderate 212 overexpression of wildtype PfFPPS/GGPPS, we conclude that the S228T variant is sufficient to 213 confer resistance independent of overexpression. Altogether these results clearly demonstrated 214 that the mechanism-of-action of MMV019313 is dependent on PfFPPS/GGPPS. 215
216

MMV019313 specifically inhibits the enzymatic activity of PfFPPS/GGPPS 217
To confirm that PfFPPS/GGPPS is the molecular target of MMV019313, we directly 218 measured MMV019313 inhibition in enzymatic assays. Consistent with a previous report, 219
purified PfFPPS/GGPPS catalyzed the production of both farnesyl(C15)-PP and 220 geranylgeranyl(C20)-PP (Jordão et al., 2013) . To measure the inhibitory effect of MMV019313, 221 we determined its IC 50 for FPP and GGPP production in two conditions. In the first "non-222 saturating" condition, substrate concentrations equaled K M values ( Figure S4 ), the concentration 223 at which the rate of reaction is half-maximal. In the second "k cat " condition, substrate 224 concentrations were saturating and the rate of reaction was maximal. Measuring inhibitor effects 225 in both "non-saturating" and "k cat " conditions increases the sensitivity for detecting different 226 types of inhibitors (competitive, non-competitive, uncompetitive). We found the IC 50 value was 227 330 nM for FPP production under "non-saturating" conditions, comparable to its EC 50 value in 228 cellular growth inhibition assays ( Figure 1B and S5). MMV019313 was identified by its IPP 229 rescue phenotype in cell growth assays wherein addition of exogenous substrate increases 230 enzymatic rates, indicating that physiological conditions are likely sub-saturating. Therefore its 231 IC 50 value measured in sub-saturating condition is more relevant for comparison to its EC 50 value 232 for growth inhibition. Under "k cat " conditions, IC 50 values were 2.0 µM for FPP production and 233 9.8 µM for GGPP production ( Figure 4A Table S3 ). In contrast, the most selective bisphosphonate identified by a previous 239 study, BPH-703, showed only a 2.6-fold selectivity for PfFPPS/GGPPS versus human FPPS and 240 3.6-fold selectivity versus human GGPPS in enzymatic assays ( Figure 4C The binding affinity estimated for the MMV019313 poses were >10 8 weaker than 272 bisphosphonate at the allylic site and >10 5 weaker than IPP at its site (Table S4 ). Therefore, the 273 modeling suggests that MMV019313 is unlikely to bind either the allylic substrate or IPP site. 274
We also attempted to dock MMV019313 into other potential binding pockets in the 275 PvFPPS/GGPPS apo structure but with inconclusive results. Optimization of the bioactivity and pharmacokinetic properties of MMV019313 360 derivatives will be priorities for their development as antimalarials. The luciferase-based 361 enzymatic assays performed in our study are robust for detection of effective inhibitors and can 362 be adapted to high-throughput screening of small molecule libraries (in contrast we found a 363 commercially-available colorimetric assay was not sufficiently sensitive) (Crowther et al., 2011) . 364
Inhibitor-enzyme structures will greatly accelerate optimization for potency against the 365 Plasmodium FPPS/GGPPS, while simultaneously minimizing binding to the human homologs. 366 P. falciparum strains overexpressing wildtype or the S228T variant, generated during this study, 367
can also be re-tooled as secondary cellular assays for on-target specificity. Increased potency 368 against blood-stage parasites will likely improve its activity against liver stage which currently is 369 not detectable at 5 µM (Van Voorhis et al., 2016). Inhibition of isoprenoid biosynthesis by 370 fosmidomycin, bisphosphonates, or MMV019313 has not been shown to block gametocyte 371 development (Lell et al., 2003; Van Voorhis et al., 2016) . The drug properties of MMV019313 372 derivatives will be optimized in standard absorption-distribution-metabolism-excretion-toxicity 373 (ADME-T) assays. For example, we found that while MMV019313 is stable to human liver 374 microsomal enzymes (t ½ > 159 min), its t ½ in mouse liver microsomes was 4 min. This metabolic 375 instability may account for a <1µM peak serum concentration following oral administration in 376 mice and will need to be addressed before derivatives can be tested in mouse models of 377
Plasmodium infection (Van Voorhis et al., 2016). 378
Finally, our study demonstrates two methodological improvements. First, we took 379 advantage of a quantitative screen for IPP chemical rescue using a range of inhibitor 380 concentrations, rather than a single high dose. The increased sensitivity allowed us to identify 381 MMV019313, though it was missed in prior screens. It also permits the screen to be performed 382 with geranylgeraniol, which is significantly less costly than IPP, since so far all identified 383 inhibitors that rescue with IPP also show at least a partial rescue of parasite growth inhibition 384 with geranylgeraniol (Yeh and Derisi, 2011; Zhang et al., 2011) . Second, we successfully 385 identified a drug-resistant mutation in chemically mutagenized Plasmodium parasites to facilitate 386 mechanism-of-action elucidation. Though the rate and type of mutations caused by EMS was not 387 characterized in our experiments, in the related apicomplexan parasite, Toxoplasma gondii EMS 388 preferentially mutated A/T residues with similar rates of transitions and transversions (Farrell et 389 al., 2014) . Notably our study identified a T-to-A transversion in PfFPPS/GGPPS in 390 MMV019313-resistant parasites which were only selected after chemical mutagenesis. 391
Characterization of the rate and type of mutations in Plasmodium parasites will facilitate 392 selection and dosing of specific chemical mutagens to optimize phenotype selection and 393 mutation identification by sequencing. Though limited, our experience suggests that the use of 394 chemical mutagens will increase successful selection for drug resistance in Plasmodium 395 parasites, which is the most common method to identify drug targets from phenotypic drug Compounds that showed IPP rescue of growth inhibition at 1 or more drug concentrations in the 441 initial 384-well high-throughput screen were re-tested in a 96-well growth assay. The highest concentration used for mutagenesis was equal to the EC 50 in order to maximize the 457 selection pressure. The mutagen was then serially diluted 1:3 to test lower concentrations that 458 might give lower mutation rates and therefore a lower frequency of passenger mutations. 459
Mutagenized parasites were washed and separated into wells of 10 mL total volume 460 (approximately 10% parasitemia, 2 % HCT). MMV019313 drug selection was applied to one 461 well for each mutagenesis condition at 600 nM (approximately EC 75 ), while the other well was 462 left untreated in order to serve as a control for whole genome sequencing. Parasites were fed 463 daily for the first week and every 3 days thereafter. Each culture was split in half every 6 days in 464 order to introduce fresh RBC. Drug pressure was maintained for 32 days, with no observable 465 parasite growth. After 32 days of selection, half of the culture from each EMS condition was 466 removed from drug pressure. In these cultures, parasites which showed resistance to 467 MMV019313 by a standard drug assay were observable after 7 days at all EMS conditions used. 468
The parasites treated with the two lowest concentrations of EMS were selected for whole 469 genome sequencing. 470 471 Whole Genome Sequencing. Plasmodium falciparum strains were sequenced by 472
Illumina sequencing as described previously (Straimer et al., 2012) . Briefly, NEBNext DNA 473 library reagents (NEB) and NEXTflex DNA barcode adapters (Bioo Scientific) were used to 474 prepare PCR-free libraries (Kozarewa et al., 2009) Transfections were carried out as previously described (Spalding et al., 2010) . Briefly, 496 400 µL fresh red blood cells were preloaded with 100 µg of both pINT, which carries the 497 bacteriophage integrase, and pRL2, which carries the gene of interest and the blasticidin 498 resistance cassette, using a BioRad Gene-Pulser Xcell Electroporator. Electroporation conditions 499 were infinite resistance, 310 V, and 950 µF using a 2 mm cuvette. Preloaded red blood cells were 500 combined with 2.5 mL ~20% schizont Dd2 attB parasites and allowed to recover for 2 days before 501 selection pressure was applied. Transfected parasites were selected with 2.5 µg/mL blasticidin 502 are were detectable by thin smear within 15 days. Integration was confirmed by PCR and identity 503 of the transgene was confirmed by sanger sequencing. 504 505 Immunoblots. Parasites expressing either ACP L -GFP or one of the FPPS/GGPPS 506 constructs generated in this study were isolated by saponin lysis and resuspended in 1xNuPage 507 LDS sample buffer (Invitrogen). Whole cell lysate was separated by SDS-PAGE using 4-12% 508
Bis-Tris gels (Initrogen) and transferred to nitrocellulose using a Trans Turbo-blot (BioRad). 509
Membranes were blocked with 3% BSA, probed with 1:5,000 monoclonal anti-GFP JL-8 510 (BioRad) overnight, washed, then probed with 1:10,000 IRDye 680LT goat-anti-mouse. The 511
Western was imaged using a Oddysey Imager (LiCor Biosciences). 512 513 Live microscopy. Infected red blood cells were treated with Hoescht to stain the nucleus. 514 PfFPPS/GGPPS (wt and S228T) and HsFPPS were toxic. Cultures were supplemented with 0.4% 535 glucose and grown to OD 600 of 0.8-1 and induced with 0.5 mM IPTG. HsGGPPS was grown 536 without supplementation to an OD 600 of 0.8-1. All cultures were induced for 4 hours at 37 °C, 537 then harvested. Cells were lysed in 20 mM HEPES pH 8.0, 150 mM NaCl, 2 mM MgCl 2 , and 538 protease inhibitor cocktail using sonication. Cleared lysates were either mixed with Talon metal 539 affinity resin (Clonetech) or purified over 5 ml HisTrap columns (GE Healthcare). His tagged 540 protein was purified with a single step purification eluting with buffer with 300 mM imidazole. 541
Proteins were dialyzed to remove imidazole and flash frozen. 
